Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MC2-25
- Development stage
- Unknown
- Lead developer
- MC2 Therapeutics
- Modality
- Peptides
- Administration
- Topical
01
Overview
MC2-25 is a first-in-class topical cream being developed by MC2 Therapeutics for the treatment of vulvar lichen sclerosus (VLS). The active ingredient is alanyl glutamine, a di-peptide that functions as an isocyanate scavenger to inhibit the carbamylation of amino acids and proteins in the skin. Formulated using the proprietary PAD Technology delivery system, MC2-25 aims to address the hypothesized root cause of VLS—the carbamylation of proteins in the vulvar region by isocyanate (a dissociation product of urea). It is currently being evaluated in Phase 2 clinical trials to assess its efficacy in reducing itch severity and other clinical signs of the disease.
- Other names
- alanyl glutamine creamalanyl-glutamine
Beyond the preview
Go deeper on MC2-25.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MC2-25.